Davis Polk advised the underwriters in connection with a follow-on offering of 2,622,950 shares of common stock of KYTHERA Biopharmaceuticals, Inc. at $45.75 per share. The offering resulted in gross proceeds of approximately $120.0 million. J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated acted as joint book-running managers and representatives of the underwriters for the offering. Leerink Swann LLC also acted as a joint book-running manager. Cowen and Company, LLC acted as co-manager. KYTHERA’s common stock is traded on the NASDAQ Global Select Market under the symbol “KYTH.”

Based in Calabasas, California, KYTHERA is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market.

The Davis Polk corporate team included partner Alan F. Denenberg and associate Peter M. Lamb. The tax team included partner Rachel D. Kleinberg and associate Catherine Paskoff Chang. Counsel Marcie A. Goldstein provided FINRA advice. The intellectual property team included partner Frank J. Azzopardi and associate Bruce Rose-Innes. Members of the Davis Polk team are based in the Menlo Park and New York offices.



Related Posts:

Leave a Reply